MRZM Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (18 Apr 2024 @ 15:03):

Stats
Today's Volume	2 180.00
Average Volume	3 717.00
Market Cap	4.43M
EPS	$0 ( 2024-03-24 )
Next earnings date	( $0 ) 2024-05-15
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0500
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2023-12-21	Braeden Lichti	Sell	3 815 294	Common stock
2023-12-21	Braeden Lichti	Sell	2	10% Secured Convertible Promissory Note
2023-06-29	Lichti Braeden	Sell	106 327	Common shares
2023-07-07	Lichti Braeden	Sell	97 000	Common shares
2023-08-29	Lichti Braeden	Sell	105 000	Common shares

INSIDER POWER
-65.59
Last 78 transactions
Buy: 7 913 036 \| Sell: 10 266 700

Marizyme, Inc. Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Marizyme, Inc. Financials

Annual	2022
Revenue:	$233 485
Gross Profit:	$179 166 (76.74 %)
EPS:	$-1.530

Q3	2023
Revenue:	$181 535
Gross Profit:	$130 546 (71.91 %)
EPS:	$-0.710

Q2	2023
Revenue:	$184 739
Gross Profit:	$135 128 (73.15 %)
EPS:	$-0.480

Q1	2023
Revenue:	$128 974
Gross Profit:	$89 699.00 (69.55 %)
EPS:	$-0.120

Financial Reports:

No articles found.

Marizyme, Inc.

Marizyme, Inc., a life science company, engages in the development and commercialization of medical technologies business. It offers DuraGraft, a one-time intraoperative vascular graft treatment for use in vascular and bypass surgeries that maintains endothelial function and structure, and other related properties. The company also develops various products using its Krillase protease-based therapeutic platform for treating complex wounds and burns, acute ischemic stroke, deep vein thrombosis, and dissolving plaque and biofilms on teeth. In addition, it focuses on developing products to mitigate the effects of ischemia reperfusion injury in other grafting and transplantation surgeries, and other indications. Further, it is involved in developing MATLOC, a point-of-care, lab-on-chip digital screening and diagnostic device platform for chronic kidney disease assessment. The company was formerly known as GBS Enterprises Incorporated. Marizyme, Inc. was incorporated in 2007 and is based in Jupiter, Florida.